EP2600715B1 - St-246-flüssigformulierungen und verfahren dafür - Google Patents

St-246-flüssigformulierungen und verfahren dafür Download PDF

Info

Publication number
EP2600715B1
EP2600715B1 EP11815188.5A EP11815188A EP2600715B1 EP 2600715 B1 EP2600715 B1 EP 2600715B1 EP 11815188 A EP11815188 A EP 11815188A EP 2600715 B1 EP2600715 B1 EP 2600715B1
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
dose
formulation
infusion
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11815188.5A
Other languages
English (en)
French (fr)
Other versions
EP2600715A4 (de
EP2600715A1 (de
Inventor
Shanthakumar R. Tyavanagimatt
Melialani A.C.L. Stone
William C. Weimers
Gopi Krishna Kasi
Peter N.K. Samuel
Tove' C. Bolken
Dennis E. Hruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of EP2600715A1 publication Critical patent/EP2600715A1/de
Publication of EP2600715A4 publication Critical patent/EP2600715A4/de
Application granted granted Critical
Publication of EP2600715B1 publication Critical patent/EP2600715B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24071—Demonstrated in vivo effect

Definitions

  • the present invention relates to novel liquid formulations of ST-246 and processes for making the liquid formulation.
  • variola virus the etiologic agent of smallpox
  • Smallpox is highly communicable and carries exceptionally high morbidity. Secondary attack rates among unvaccinated members of households in which someone had smallpox have been reported to range from 30% to 80%. Mortality rates range from 1% for variola minor to 30% for variola major. With the advent of biowarfare as an instrument of terrorism, smallpox can no longer be thought of as a disease of historic impact only.
  • antiviral drugs used alone or potentially in combination with vaccination can be used to treat individuals during the window of vulnerability which occurs prior to development of protective immunity. Additionally, antiviral drugs could also be used in the treatment of zoonotic poxvirus disease inhumans, such as monkeypox.
  • ST-246 (4-trifluoromethyl- N -(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide), has recently emerged as a potent candidate against orthopoxvirus.
  • ST-246 (4-trifluoromethyl- N -(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide), has recently emerged as a potent candidate against orthopoxvirus.
  • Several studies evaluating ST-246 for activity against orthopoxviruses have demonstrated excellent in vitro and in vivo efficacy (3, 4).
  • ST-246 When evaluated in vitro against vaccinia virus (VV), cowpox virus (CV), ectromelia virus (ECTV), monkeypox, camelpox, and variola viruses, ST-246 inhibited virus replication by 50% (50% effective concentration [EC50]) at or below a concentration of 0.07 ⁇ M. With animal models using lethal infections with ECTV, VV, or CV, ST-246 was reported to be nontoxic and highly effective in preventing or reducing mortality even when treatments were delayed up to 72 h post-viral inoculation (3, 4). ST-246 was also evaluated with the nonlethal mouse tail lesion model using intravenous W.
  • ST-246 When ST-246 was administered orally twice a day at 15 or 50 mg/kg of body weight for 5 days, the tail lesions were significantly reduced (4). Most recently, an infant was given ST-246 as an FDA-authorized emergency treatment for eczema vaccinatum which developed after exposure to the parent's predeployment military smallpox immunization (5).
  • the present invention provides a liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246 and hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl -ether- ⁇ -cylodextrin, and further comprising one or more pharmaceutically acceptable ingredients.
  • the present invention further provides a process of making a liquid formulation according to the present invention comprising the steps of: a) mixing ST-246 with said cyclodextrins in a pharmaceutically acceptable liquid carrier; and b) optionally filtering the mixture of step a).
  • the present invention also provides a unit dosage liquid formulation comprising: a) ST-246 content ranging from about 2 mg/ml to about 20 mg/ml; and b) hydroxypropyl- ⁇ -cyclodextrin content ranging from about 12.5 mg/ml to about 40 mg/ml.
  • the present invention also provides a process for preparing a water-soluble solid ST-246 pharmaceutical formulation comprising: a) mixing ST-246 with hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl -ether- ⁇ -cyclodextrin in a pharmaceutically acceptable liquid carrier; and b) optionally filtering the mixture of step a); and c) lyophilizing said mixture.
  • the present invention provides a safe and effective liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246 and cyclodextrin, and optionally further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carrier, excipient, diluent, additive, filler, lubricant, solubilizer, preservative and binder.
  • the cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl-ether- ⁇ -cylodextrin. In one embodiment, hydroxypropyl- ⁇ -cyclodextrin has a degree of substitution between about 4 to about 8.
  • hydroxypropyl- ⁇ -cyclodextrin is present in amounts ranging from about 10% to about 50% by weight, more preferably about 20% to about 40% by weight.
  • the liquid pharmaceutical formulation is adjusted to have pH between about 3 and 12, more preferably between about 3 and 10.
  • the instant liquid pharmaceutical formulations are suitable for oral, parenteral, mucosal, transdermal or topical administration.
  • the invention also relates to the liquid pharmaceutical formulation for use in methods of treating orthopoxvirus infections comprising administering to a subject in need thereof the liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246 and hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl- ⁇ -cyclodextrin and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carrier, excipient, diluent, additive, filler, lubricant and binder.
  • cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin.
  • hydroxypropyl-p-cyclodextrin has a degree of substitution between about 4 to about 8.
  • cyclodextrin is sulfobutyl-ether- ⁇ -cylodextrin.
  • the invention also relates to a liquid pharmaceutical formulation for use in a method of treating eczema vaccinatum comprising administering to a subject in need thereof a therapeutically effective amount of instant liquid formulation.
  • the instant liquid pharmaceutical formulation can be administered via oral, parenteral, mucosal, transdermal or topical route of administration.
  • the instant invention also provides a process of making the liquid formulation of the present invention comprising the steps of a) mixing ST-246 with the cyclodextrin according to the claims and b) optionally filtering the mixture of step a).
  • the instant process comprises ST-246 which is selected from the group consisting of polymorphic Form I, Form II, Form III, Form IV, Form V and Form VI.
  • cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin.
  • hydroxypropyl- ⁇ -cyclodextrin has a degree of substitution between about 4 to about 8.
  • cyclodextrin is sulfobutyl -ether- ⁇ -cylodextrin.
  • the instant process comprises mixing ST-246 with cyclodextrin in a pharmaceutically acceptable liquid carrier for about 15 min to 72 hours.
  • the instant process comprising mixing ST-246 with cyclodextrin in a pharmaceutically acceptable liquid carrier at a temperature range from about 28°C to about 70°C.
  • the pharmaceutically acceptable liquid carrier is water.
  • a unit dosage liquid formulation comprising: a) ST-246 content ranging from about 2 mg/ml to about 20 mg/ml; b) hydroxypropyl- ⁇ -cyclodextrin content ranging from about 12.5 mg/ml to about 40 mg/ml; and c) optionally comprising mannitol, trehalose dehydrate, lactose monohydrate, and purified water such that the total volume of the liquid formulation is about 100 ml.
  • the pH is adjusted to a range from about 3.0 to about 5.0 using 0.1 HCL/NaOH.
  • the pH is adjusted to a range from about 3.0 to about 5.0 using citrate buffer.
  • a unit dosage liquid formulation comprising: a) ST-246 ranging from about 2 mg/ml to about 20 mg/ml; b) hydroxypropyl- ⁇ -cyclodextrin content ranging from about 12.5 mg/ml to about 40 mg/ml; and c) optionally comprising one or more pharmaceutically acceptable ingredient selected from the group consisting of: polyethylene glycol 400, polysorbate 80, polyethylene glycol 300, and purified water such that preferably, the total volume of the liquid formulation is about 100 ml.
  • a pH is adjusted to 3.0 to 5.0 using 0.1 HCL/NaOH.
  • the pH is adjusted to a range from about 3.0 to about 5.0 using citrate buffer.
  • compositions or “pharmaceutical formulation” is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • half-life is a pharmacokinetic term used to indicate the length of time necessary to eliminate 50% of the remaining amount of drug present in the body.
  • AUC pharmacokinetic term used to refer a method of measurement of bioavailability or extent of absorption of a drug based on a plot of an individual or pool of individual's blood plasma concentrations sampled at frequent intervals; the AUC is directly proportional to the total amount of unaltered drug in the patient's blood plasma.
  • a linear curve for a plot of the AUC versus dose indicates that the drug is being released slowly into the blood stream and is providing a steady amount of drug to the patient; if the AUC versus dose is a linear relationship this generally represents optimal delivery of the drug into the patient's blood stream.
  • a non-linear AUC versus dose curve indicates rapid release of drug such that some of the drug is not absorbed, or the drug is metabolized before entering the blood stream.
  • C- max (i.e., “maximum concentration”) is a pharmacokinetic term used to indicate the peak concentration of a particular drug in the blood plasma of a patient.
  • T max (i.e., "time of maximum concentration” or “time of C max ”) is a pharmacokinetic term used to indicate the time at which the C max is observed during the time course of a drug administration.
  • a dosage form that would include an immediate release as well as a gastric retentive component would have a T max that is higher than the C max for an immediate release dosage form, but lower than the T max for a purely gastric retentive dosage form.
  • the term "subject" for purposes of treatment includes any subject, and preferably is a subject who is in need of treatment of an orthopoxvirus infection or related condition.
  • the subject is typically an animal, more typically is a mammal.
  • the mammal is a human.
  • chemically modified cyclodextrin refers to one or more chemically modified cyclodextrins where there is independently more than one degree of substitution that can vary from about 0.5 to about 10.0.
  • the degree of substitution (the mean number of functional groups per glucose unit) of the chemically modified cyclodextrin can vary as need to provide the necessary solubility and stability of the ST-246.
  • the degree of substitution can be between from about 0.5 to about 10.0.
  • the degree of substitution can be between 2-hydroxypropyl- ⁇ -cyclodextrin.
  • (of substituted hydroxy functional groups per glucose unit) can be, for example, between about 4.0 and 8.0. Degree of substitution can be determined by mass spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy using known techniques.
  • the term "poorly soluble therapeutic agent” refers to a compound having biological activity and a solubility in water of less than about 1 mg/mL in buffer of pH 1.2 to 7 at 20°C25 C and 37 degree.
  • the poorly soluble therapeutic agent is an organic compound that has a molecular weight of less than 1500 g/mol, and preferably less than 500 g/mol.
  • the poorly soluble therapeutic agent is a compound, for example, an organic compound, having an aqueous solubility of less than about 0.5 mg/mL, less than about 0.3 mg/mL, or less than about 0.1 mg/mL, at pH 7 and 20°C.
  • terapéuticaally effective amount refers to an amount of ST-246 that is nontoxic but sufficient in preventing or ameliorating the severity of orthopoxvirus infection or related condition.
  • percent means the percent of the component indicated in the composition based on the amount of the carrier present in the composition, on a weight/weight (w/w), weight/volume (w/v) or volume/volume (v/v) concentration, as indicated with respect to any particular component, all based on the amount of the carrier present in the composition.
  • different types of carriers can be present in an amount of up to 100% as indicated, which does not preclude the presence of the API, the amount of which can be indicated as a % or as a certain number of mg present in the composition or a certain number of mg/mL present, where the % or mg/mL is based on the amount of the total carrier present in the composition.
  • Certain types of carriers can be present in combination to make up 100% of the carrier.
  • a term "pharmaceutically acceptable carrier” as used herein is non-toxic or has certain toxic attributes that are not dose limiting to achieve therapeutic advantages to recipients at the dosages and concentrations required and is compatible with other ingredients of the formulation.
  • pharmaceutically acceptable excipient includes vehicles, adjuvants, or diluents or other auxiliary substances, such as those conventional in the art, which are readily available to the public, and which are non-toxic or have acceptable toxicities to recipients at the dosages and concentrations employed, and is compatible with other ingredients of the formulation.
  • pharmaceutically acceptable auxiliary substances include pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, preservatives, solubilzers, wetting agents and the like.
  • Cylodextrins are water soluble sugar oligomers. Many different cyclodextrins exist and are distinguished from each other by the number of glucopyranose units. The most common cyclodextrins are composed of six, seven or eight alpha-D-glucose units. Cyclodextrins form structures having cavities which are hydrophilic on the outside and lipophilic on the inside. The number of glucose units determines the size of the cavity. The hydrophilic exterior gives cyclodextrins their solubility in aqueous solutions while the lipophilic interior or cavity provides an environment which is often attractive to other hydrophobic molecules.
  • Cyclodextrins can take up the entirety of a molecule or only a part thereof into the cavity. The stability of the resulting complex depends on how well the drug molecule fits into the cyclodextrin cavity.
  • Cyclodextrins suitable for use in the compositions, formulations, and methods herein disclosed are generally cyclic oligosaccharides with a cone-like shape.
  • the interior of the cone acts as a hydrophobic cavity, while the exterior of the cone is hydrophilic.
  • the former property enables cyclodextrins to form inclusion complexes with a wide variety of lipophilic molecules or portions thereof, which "fit" into the cavity while the latter property facilitates aqueous solubility.
  • Cyclodextrin derivatives have been extensively studied for use as parenteral drug carriers owing to their high water solubility and low toxicity. (Fromming & Szejtli, J. (1994).
  • Chemically modified cyclodextrins can include derivatives of ⁇ -cyclodextrin, ⁇ -cyclodextrin, Gamma cyclodextrin or ⁇ -cyclodextrin.
  • Chemically modified cyclodextrins can include, but are not limited to methyl- ⁇ -cyclodextrin, 2-6-di-O-metbyl- ⁇ -cyclodextrin, randomly methylated- ⁇ -cyclodextrin, ethyl- ⁇ -cyclodextrin, carboxymethyl- ⁇ -cyclodextrin, diethylaminoethyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ cyclodextrin, 3-hydroxypropyl- ⁇ -cyclodextrin, 2, 3-dihydroxypropyl- ⁇ -cyclodextrin, and sulfobutyl ether- ⁇ -cyclodextrin.
  • Chemically modified cyclodextrins can include 2-hydroxypropyl- ⁇ -cyclodextrin, 3-hydroxypropyl- ⁇ -cyclodextrin, 2, 3-dihydroxypropyl- ⁇ -cyclodextrin, and sulfobutyl ether- ⁇ -cyclodextrin.
  • the liquid pharmaceutical formulation according to the invention comprises hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl- ⁇ -cyclodextrin. More preferably, the chemically modified cyclodextrin is 2-hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl ether- ⁇ -cyclodextrin.
  • the degree of substitution for 2-hydroxypropyl- ⁇ -cyclodextrin is between 4 and 8.
  • the preparation of pharmaceutical formulations as herein disclosed involves dissolving the chemically modified cyclodextrin in a suitable volume of aqueous carrier medium (for example, water for injection), removal of oxygen (for example, with nitrogen, inert gas, or freeze-thaw under vacuum), followed by the gradual addition of ST-246 to the cyclodextrin solution under vigorous stirring until essentially all of the ST-246 has been complexed and is in solution.
  • aqueous carrier medium for example, water for injection
  • oxygen for example, with nitrogen, inert gas, or freeze-thaw under vacuum
  • ST-246 to the cyclodextrin solution under vigorous stirring until essentially all of the ST-246 has been complexed and is in solution.
  • the temperature of the cyclodextrin solution can be between 0°C-80°C.
  • the temperature of the cyclodextrin solution is maintained between about 2°C -70°C degrees.
  • the solution can be brought to a final volume with de-oxygenated aqueous carrier medium.
  • the solution can then be sterilized, for example, by filtration and/or aseptically transferred to vials or ampoules.
  • the solution can be transferred directly to ampoules for sterilization by autoclaving or irradiation.
  • the vials or ampoules can be sealed under an inert gas, such as nitrogen.
  • the molar ratio of ST-246 to chemically modified cyclodextrin can be for example about 0.03 mol/mol.
  • the molar ratio of ST-246 to chemically modified cyclodextrin is about 0.01 to about 1.0 . More preferably, the molar ratio of ST-246 to chemically modified cyclodextrin is about 0.03 to 0.15 mol/mol.
  • compositions and single unit dosage forms comprising a compound of the invention, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, are also encompassed by the invention.
  • Individual dosage forms of the invention can be suitable for oral, mucosal (including sublingual, buccal, rectal or nasal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), transderal, and topical administration.
  • compositions and dosage forms of the invention comprise a compound of the invention, or a pharmaceutically acceptable prodrug, polymorph, salt, solvate or hydrate thereof.
  • ST-246 exists in different crystalline forms denominated Form I, Form II, Form III, Form IV, Form V, and Form VI.
  • Form I is a monohydrate crystalline form of ST-246 which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2 ⁇ of about: 7.63,10.04,11.47,14.73,15.21,15.47,16.06,16.67,16.98,18.93,19.96,20.52,20.79,22.80,25.1 6,26.53,27.20,27.60,29.60,30.23,30.49,30.68,31.14,33.65,34.33,35.29 ,35.56,36.30,37.36,3 8.42,38.66 degrees.
  • Form II is an anhydrate crystalline form of ST-246.
  • Form II shows an X-ray powder diffraction pattern having characteristics according to Figure 12 .
  • Form III is a monohydrate crystalline form of ST-246 which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2 ⁇ of about: 6.71,9.05,12.49, 13.03, 13.79, 14.87, 15.72, 16.26, 16.74, 18.10, 18.43,19.94,21.04,21.51,23.15,23.51,25.32,26.24,26.87,27.32,27.72,28.55,29.08,29.50,29. 84,31.27,33.48, 35.36,39.56 degrees.
  • Form IV is an anhydrate crystalline form of ST-246.
  • Form IV shows an X-ray powder diffraction pattern having characteristics according to Figure 13 .
  • Form V is a hemihydrate crystalline form of ST-246.
  • Form VI shows an X-ray powder diffraction pattern having characteristics according to Figure 14 .
  • Form VI is a monohydrate crystalline form of ST-246.
  • Form VI shows an X-ray powder diffraction pattern having characteristics according to Figure 15 .
  • ST-246 Form I is the preferred polymorph of ST-246. It appears to be the thermodynamically most stable form, as all other get converted to Form-I.
  • ST-246 Form I is stable and hence can be stored at ambient conditions. Form I has not been shown to convert to another polymorphic form under several environmental and process conditions that a drug could experience during various stages of manufacturing and storage. Some of the conditions tested include storage at high temperature and high humidity, room temperature and high humidity, low humidity, up to 60°C, capsule manufacturing using wet granulation and drying, during milling or micronization process, in suspension, long term storage at room temperature. Further, Form-I is non hygroscopic and hence does not absorb moisture even at 90% relative humidity conditions. Form I is reliably manufactured by the commercial crystallization process with more than 99.0% purity and with any single impurities not more than 0.15%. The instant Examples describe experiments with ST-246 Form I. However, ST-246 Form II, Form III, Form IV and Form V can be used to obtain similarly stable liquid ST-246 formulations.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to capsules and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and can be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990 ).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
  • Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
  • preservatives e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid.
  • the preparations can also contain buffer salt
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
  • hydrogenated vegetable oil e.g., peanut oil, cottonseed oil
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intra-arterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • water for Injection USP Water for Injection USP
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
  • Transdermal and topical dosage forms of the invention include, but are not limited to, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th eds., Mack Publishing, Easton Pa. (1990 ); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985 ).
  • Transdermal dosage forms include "reservoir type” or "matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
  • Suitable excipients e.g., carriers and diluents
  • other materials that can be used to provide transdermal and topical dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th eds., Mack Publishing, Easton Pa. (1990 ).
  • the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied can also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • Intravenous administration dosage and duration
  • Example 4 a population PK model was developed to assess the disposition of ST-246 following IV infusion in male and female uninfected cynomolgus monkeys.
  • a three-compartment model with dose as covariate described the nonlinear PK (reduced clearances at higher doses) of IV ST-246. Diagnostic plots and a visual predictive check confirmed that the observed data were reasonably well described by the proposed model. Allometric scaling of PK parameters in monkeys was performed to determine PK parameters in humans.
  • a targeted range of exposure was determined a priori based on observed concentration-time profiles in human subjects treated with oral ST-246.
  • Monte Carlo simulations were performed to determine candidate dosing levels of IV ST-246 that would results in similar AUC, C max , and C min values as those previously observed in healthy uninfected humans following repeated oral administration of 400 and 600 mg ST-246.
  • Numerous different possible dosing regimens were simulated. Predicted AUC and C max values were compared first to those observed after oral doses. C min values were compared thereafter. In general, a regimen that can generate equivalent C min would require longer infusion time with higher AUC values than the regimen that generates equivalent AUC and C max .
  • Repeated IV infusion of 115 mg QD over 5 hours or 65 mg BID over 1 hour would provide AUC and C max values at steady state very similar to those observed after oral doses of 400 mg.
  • Repeated IV infusion of 80 mg BID over 2 hours resulted in C min values at 12 and 24 hours similar to those observed following oral administration of 400 mg QD in healthy uninfected humans.
  • repeated IV infusion of 145 mg QD over 4 hours or 95 mg BID over 1 hour would provide AUC and C max values at steady state very similar to those observed after oral doses of 600 mg.
  • repeated IV infusion of 85 mg BID over 1 hour resulted in C min values at 12 and 24 hours similar to those observed following oral administration of 600 mg QD in healthy uninfected humans.
  • the instant liquid pharmaceutical formulation can be administered intravenously.
  • about 50 to about 500 mg, more preferably about 200mg to about 400 mg, most preferably about 300 mg of ST-246 is infused per single session of intravenous administration.
  • the treatment is carried out for a period ranging from about 7 to about 30 days, preferably, about 7 to about 15 days.
  • the duration of each session of intravenous administration is from about 2 to about 24 hours.
  • the treatment carried out continuously over the course of treatment at a dosage of about 50 to about 500 mg of ST-246 per day.
  • the treatment may be carried out during two sessions per day, wherein the duration of each session is from about 2 to about 12 hours.
  • ST-246 an anti-smallpox small molecule and is intended to be administered by various routes of administration, is poorly soluble in water and in pharmaceutically acceptable pH buffers in the range of 2-11.
  • the preferred formulation for injectable formulation is a liquid formulation prepared using pharmaceutically acceptable additives. To obtain liquid formulation, the solubility of the drug should be such that therapeutically effective amount of drug can be delivered safely. Further, the formulation should be able to withstand dilution in commonly used intravenous dilution fluids such as normal saline and in blood upon injection. Since ST-246 is an insoluble drug, it poses challenges to development of safe and effective IV solution formulation.
  • composition which provides adequate solubility of ST-246 and can be delivered to subjects in safe and effective manner.
  • ST-246 polymorphic Form I was used.
  • the solutions of cosolvents included polyethylene glycol (PEG) 400, propylene glycol, ethanol;
  • Solubility of ST-246 in several oils including sesame oil, soybean oil and corn oil was investigated.
  • PEG 400 demonstrated the greatest ST-246 solubilization followed by Labrasol®, ethanol, Propylene Glycol, Tween 80, Cremophor EL and Cremophor RH-40, all of which were identified as potential intravenous formulation candidates.
  • PEG 400 and ethanol were selected for cosolvent combination analysis.
  • the absolute solubility of ST-246 in oils was less than 5 mg/ml eliminating them as possible IV formulation candidates.
  • Example 2 Composition of ST-246 in various concentrations of cosolvents/surfactant in water.
  • Table 5 is a summary of the solubilization efficiency as measured by the slope of the trend lines of ST-246 concentration plotted against % w/v of the excipients in water; the larger the slope, the greater the solubilization efficiency.
  • the excipients are ranked in order based upon the magnitude of the solubilization efficiency with the excipient with the highest ST-246 solubilization efficiency in aqueous solutions ranked as number one.
  • Column 5 represents the solubility of ST-246 determined in mg/ml in pure (neat 100%) excipients.
  • Cyclodextrins contain a torus-shaped ring with a polar hydrophilic outside and an apolar hydrophobic cavity.
  • Figure 4 illustrates the structure of one type of cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD) and Table 6 provides characteristics summary of cyclodextrins.
  • Table 7 summarizes solubility of ST-246 in aqueous solutions of various grades of cyclodextrins at concentrations ranging from 20 to 40%.
  • the range of ST-246 solubilized by cyclodextrin was 1.5 to 11 mg/ml at 37°C, with HP- ⁇ -CD out-performing sulfobutylether-derivatized cyclodextrin (SBECD).
  • SBECD sulfobutylether-derivatized cyclodextrin
  • Table 8 Solubility of ST-246 in Aqueous Solutions of Substituted ⁇ -Cyclodextrins at 37°C.
  • Figure 5 summarizes solubility of ST-246 as a function of cyclodextrin concentration.
  • the solubility of ST-246 increases with increased HP- ⁇ -CD concentration.
  • HP- ⁇ -CD provided for higher ST-246 solubility as compared to SBECD.
  • Solubility data presented in Table 10 suggest that presence of cosolvent (PEG 400) or non-ionic surfactant (tween 80) does not improve ST-246 solubility in HP- ⁇ -CD and hence no further work was done to evaluate ternary complexation.
  • ST-246, Form I, II, III, IV, V and VI were formulated for liquid administration.
  • Suitable dosage forms comprises ST-246 ranging from about 2 mg/ml to about 20mg/ml and HPBCD, ranging from about 12.5 mg/ml to about 40 mg/ml.
  • the formulations further comprises mannitol, trehalose dehydrate, lactose monohydrate, and purified water such that the total volume of the liquid formulation is about 100ml.
  • the pH may be adjusted and maintained form 2.5 to 6.0, by using HCL/NaOH, citric acid/Na citrate buffer, and other buffers including but not limited to acetate, tartarate, glycine, glucoronic acid.
  • compositions of 12.5 mg/mL ST-246 IV formulations Composition # 25 26 27 28 29 30 31 32 33 34 35 36
  • Ingredient Quantity for 100 mL (g) ST-246 1 1 1 1 1 1 1 1 1 1 1 1 1 HPBCD 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 Mannitol - - - 1 1 1 - - - - - Trehalose Dihydrate - - - - - - 1 1 1 - - - Lactose Monohydrate - - - - - - - - - - 1 1 1 pH adjusted to 3.0 to 5.0 using 0.1 N HCl/NaOH - q.s.
  • compositions of 20 mg/mL ST-246 IV formulations Composition # 49 50 51 52 53 54 55 56 57 58 59 60 Ingredient Quantity for 100 mL (g) ST-246 2 2 2 2 2 2 2 2 2 2 2 2 2 2 HPBCD 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 Mannitol - - - 1 1 1 - - - - - - Trehalose Dihydrate - - - - - - 1 1 1 - - - Lactose Monohydrate - - - - - - - - - - - 1 1 1 pH adjusted to 3.0 to 5.0 using 0.1 N HCl/NaOH - q.s.
  • Suitable dosage forms comprises ST-246 ranging from about 2 mg/ml to about 20mg/ml and HPBCD, ranging from about 12.5 mg/ml to about 40 mg/ml.
  • the formulations further comprise polyethylene glycol 400, polysorbate 80, polyethylene glycol 300, and purified water up to 100 ml.
  • the pH may be adjusted and maintained form 2.5 to 6.0, by using HCL/NaOH, citric acid/Na citrate buffer, and other buffers including but not limited to acetate, tartarate, glycine, glucoronic acid.
  • Table 22 summarizes ranges for ST-246 and HPBCD in various formulations.
  • Table 22 - Compositions of ST-246 IV formulations by varying the HPBCD concentrations Composition # 121 122 123 124 125 126 Ingredient Quantity for 100 mL (g) ST-246 2 2 2 5 10 20 HPBCD 12.5 20 30 40 40 40 Purified water Q.S. (mL) 100 100 100 100 100 100 100 100 100 100 100 100
  • Intravenous formulations of ST-246 at 5-20 mg/mL were found to be compatible with 0.9% NaCl for at least 48 hours at 1:2 dilution (expected dilution in clinical situation) when stored at RT and refrigerated conditions.
  • Intravenous (IV) administration of ST-246 formulation, comprising HPBCD were evaluated in mice, rabbits and NHP. The resulting pharmacokinetic parameters have been compared with those obtained after oral administration. The results of these studies suggest that intravenous ST-246 formulations exhibit similar pharmacokinetic parameters as compared to oral ST-246 formulations when administered in subjects in need thereof. Furthermore the ST-246 formulations comprising HP- ⁇ -CD appeared to be safe and the pharmacokinetic parameters were acceptable.
  • PK profile in Mouse Three preliminary mouse studies (ASM246, ASM250 and ASM257) unequivocally demonstrated that short infusions of ST-246 intravenous formulations provided exposure similar to that obtained after ST-246 oral dosing, but at much lower doses. Specifically, ten-minute ST-246 infusion at four doses (3, 10, 30 and 75 mg/kg) were evaluated in female CD-1 mice and the plasma concentrations were measured at the end of these infusions. Further, those concentrations were, as expected, the peak plasma concentrations and the average plasma concentration at the end of the 10-minute infusion of 75 mg/kg was 238, 333 ng/mL.
  • Table 24 summarizes the C max (ng/mL) plasma concentrations and the AUC 0-24 (hr ⁇ ng/mL) for the ST-246 intravenous formulation and the pivotal oral formulation parameters. Table 24 - Comparison of C max and AUC Values Dose (mg/kg) Formulation Route C max (ng/mL) AUC 0-24 (hr ⁇ ng/mL) C max Ratio* AUC Ratio* IV/PO IV/PO Study ASM246 M F M F F F 2.3 32% HPBCD IV Bolus 19977 22403 73327 87757 0.2 0.08 7.6 53834 37589 170100 218136 0.4 0.2 34.3 191174 162327 797725 873097 1.6 0.8 Study ASM250 3 40% HPBCD Slow IV Bolus (5-min) 78428* 100000* - - 30 148918* 300000* - - Study ASM257 30 40% HPBCD 5-min Infusion ND 120051 - -
  • PK profile in Rabbits Intravenous ST-246 formulations comprising HP- ⁇ -CD were administered to rabbits. Further, tolerability and pharmacokinetic parameters were evaluated after 5-minute slow IV push injections via the marginal ear vein in two male and two female naive New Zealand White rabbits at doses of 3, 30, and 60 mg/kg ST-246.
  • the peak plasma concentration using a 15-minute infusion at 3 mg/kg were 7225 ng/mL and 4345 ng/mL for male and female rabbits, respectively.
  • the observed C max plasma concentrations and the AUC values were higher and the plasma elimination half-lives was longer for oral administration.
  • the summary of the pharmacokinetic parameters in rabbits after oral and intravenous administartion are shown in Table 25.
  • PK profile in Cynomolgus monkeys The study design included three groups of two male and two female monkeys.
  • ST-246 was administered at 1, 3, and 10 mg/kg over a 4-hr intravenous infusion period by way of an implanted Vascular Access Port (VAP).
  • VAP Vascular Access Port
  • the concentration of HP- ⁇ -CD in the infusion fluid was 13.3 % w/v.
  • Plasma samples were collected pre-dose, and at 0.5, 1, and 2 hours after the start of the infusion as well as at the end of infusion (EOI) (4.0 hour ⁇ 10 minutes), 0.25, 0.5, and 1 hour after the EOI and at 6, 8, 12, 16, 20, 24 and 48 hours after the start of the infusion to accurately determine the terminal elimination half-life.
  • EOI end of infusion
  • C max (ng/mL) plasma concentrations and the AUC 0-24 (hr ⁇ ng/mL)) in cynomolgus monkeys at 1, 3 and 10 mg/Kg and the Oral formulation at 3, 10, 20 and 30 mg/kg over time are shown in the Table 26.
  • a liquid formulation has been developed for IV administration of ST-246 containing hydroxypropyl beta cyclodextrin in aqueous solution.
  • the tolerability and pharmacokinetics of this formulation have been evaluated in mice, rabbits and NHP in order to determine the optimal administration strategy. The results are compared with the pharmacokinetics observed after oral administration.
  • ST-246 was administered by oral gavage as a methylcellulose suspension formulation with 1% Tween 80 to BALB/c mice (Charles River), New Zealand White (NZW) rabbits (Harlan), and cynomolgus monkeys (NHP, Charles River). NHP were administered ST-246 immediately after feeding to increase the bioavailability (6).
  • Female BALB/c mice were administered the suspension formulation via oral gavage at doses of 30, 100, 300, and 1000 mg/kg. Concentrations of ST-246 were measured by taking blood samples from three mice at each of the following time points: 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post dose.
  • Three male and three female NZW rabbits were administered ST-246 orally as a suspension formulation at a dose of 100 mg/kg.
  • a slow push (5 minute) IV injection of a solution formulation of ST-246 was administered to a small number of catheterized female BALB/c mice at doses of 3, 30, and 100 mg/kg. Blood samples were collected at 5, 15, 30 minutes and 1, 2, 4, 8, and 24 hours after IV administration for the 10 and 30 mg/kg dose, but only at 2 and 4 hours after dose administration for the 100 mg/kg dose. Patency difficulties in the catheters limited the number of mice per time point to no more than two.
  • a 10-minute IV infusion of ST-246 was given via a surgically implanted jugular cannula at doses of 3, 10, 30, and 75 mg/kg to catheterized naive female CD-1 mice. Blood samples were collected at 5, 10 (end of infusion), 20, 30 minutes, and 1, 2, 4, 8, 24 hours post dose. Blood samples for each time point were collected from three animals as terminal bleeds.
  • ST-246 was infused via the marginal ear vein at doses of 3, 30, and 60 mg/kg over a 5-minute period and at 3 mg/kg over a 15-minute period followed by blood sampling at multiple times in order to generate complete plasma concentration time curves.
  • Two male and two female rabbits were used for each dose group.
  • blood samples were collected at 10 minutes (5 minutes after the end of the injection), 20 and 30 min, 1, 2, 4, 8, and 24 hours after administration.
  • Blood samples for the 15-minute IV infusion were taken at the end of the infusion (15 minutes), 25 and 45 minutes, and 1, 2, 4, 8, and 24 hours after the beginning of the infusion.
  • Nonhuman primates were prepared for ST-246 administration by surgical implantation of a catheter in the femoral vein that was routed to a subcutaneous port. Doses of 1, 3, 10, 20, and 30 mg/kg were infused over 4 hours to groups consisting of two male and two female NHP. Two additional groups were administered the 20 and 30 mg/kg doses over 6 hours. For the 4 hour IV infusion group, blood was collected for ST-246 analysis at the following time points: 0.5, 1, 2, 4 (end of infusion), 4.25, 4.5, 5, 6, 8, 12, 16, 20, 24, and 48 hours after the start of the infusion.
  • the samples were collected at the following time points: 1, 2, 4, 6 (end of infusion), 6.25, 6.5, 8, 10, 12, 16, 20, 24, and 48 hours after initiation of dose administration. Blood samples were collected at multiple time points to allow complete characterization of the plasma concentration time curve and estimate the pharmacokinetic parameters.
  • Two groups of 4 males and 4 females were used in a second study that was conducted after a 10 day washout. In the second phase, the pharmacokinetic parameters were characterized over the course of a twice daily (BID) regimen for doses of 10 and 15 mg/kg that were infused over two 4 hour infusion periods initiated 12 hours apart.
  • BID twice daily
  • the total daily doses were 20 and 30 mg/kg, equivalent to the two highest doses that had been evaluated during both 4 and 6 hour IV infusions.
  • blood was collected at the following time points for ST-246 concentration determination: 0.5, 2, 4 (end of first infusion), 4.5, 6, 8, 12, 12.5, 14, 16 (end of second infusion), 16.5, 18, 20, 24, 32, 36 and 60 hours after the beginning of infusion of the first dose.
  • ST-246 concentrations in mice, rabbit and NHP plasma were measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
  • Blank plasma for calibration curves and quality control samples were purchased from Bioreclamation, Inc. (Westbury, NY).
  • Two different extraction methods were used over the course of these studies. Both methods were validated following the FDA bioanalytical validation guidelines (7).
  • the extraction of ST-246 from plasma was carried out by simple protein precipitation by the addition of 9 parts methanol (450 ⁇ L) containing the isotopic internal standard to 1 part (50 ⁇ L) plasma sample.
  • the second extraction method was a liquid-liquid extraction (LLE) method.
  • Plasma samples were diluted 1:1 with methanol containing internal standard and three volumes of water added. These mixtures were vortexed and the entire volume transferred to the extraction plate (Biotage SLE, 200 mg). Minimal vacuum was applied to load the samples and then allowed to stand for 5 minutes. Methyl tertiary-butyl ether was added to all wells (500 ⁇ L/well) and eluted with minimal vacuum. The solvent was evaporated to dryness under nitrogen (set at 50°C and 30-40 L/min). The samples were reconstituted (0.05% acetic acid and 0.05% ammonium hydroxide in methanol/water; 65:35, v/v) by gently vortexing the plate afterwards.
  • LLE liquid-liquid extraction
  • the chromatographic separation was performed using a Phenyl-Hexyl column (50 x 2.0 mm, 5 ⁇ m, Phenomenex) with a Securityguard column, using 0.05% ammonium hydroxide and 0.05% acetic acid in MeOH/H 2 O (65:35,v/v) at a flow rate of 400 ⁇ L/min for the mobile phase.
  • a 3200 (or 4000) Qtrap (AB Sciex) mass spectrometer was tuned to the multiple reaction monitoring (MRM) mode to monitor the m/z transitions, 375.0/283.2 for ST-246 and m/z 341.1/248.8 for the internal standard, in negative ion mode.
  • MRM multiple reaction monitoring
  • the MS/MS response was (1/x 2 ) weighted linearly over the concentration range from 5.00 to 2000 ng/mL.
  • the accuracy and precision of the method were within the acceptable limits of ⁇ 20% at the lower limit (5.0 ng/mL) of quantitation and ⁇ 15% at other concentrations.
  • Pharmacokinetic parameters were analyzed with WinNonlin Phoenix version 6.1 (Pharsight, Mountain View, CA) software initially using noncompartmental analysis, with compartmental analysis conducted later for some of the studies. The following parameters were estimated: terminal elimination half-life ( t 1/2 ), the area under the curve (AUC last ), the area under the curve extrapolated to infinity (AUC 0-inf ), clearance (CL), and the steady state volume of distribution (V ss ). The peak plasma concentrations (C max ) and the time to peak plasma concentration (T max ) were determined graphically from the experimental values.
  • catheterized female CD-1 mice were administered 10-minute IV infusions at doses of 3, 10, 30 and 75 mg/kg. Although mice that received the highest dose, 75 mg/kg, had an unsteady gait after the end of infusion, they recovered within 2-3 hours. All other doses were well-tolerated when administered as 10-minute IV infusions. The correlation between the clinical signs and the end of the infusions suggests, but does not prove, that the high C max concentrations were responsible for the clinical signs in mice after IV administration at higher doses.
  • the 15-minute IV infusion of 3 mg/kg resulted in a mean C max concentration of 5.79 ⁇ g/mL, only two-fold higher than the 2.86 ⁇ g/mL observed after oral administration of 100 mg/kg (Table 2).
  • the AUC 0-24 value for the 3 mg/kg IV dose was only 2.38 hr ⁇ ⁇ g/mL while AUC 0-24 value for the 100 mg/kg oral dose was 19.8 hr ⁇ ⁇ g/mL, only 8.3-fold higher exposure for a 33-fold higher dose.
  • the AUC 0-24 values observed after the 30 mg/kg dose via intravenous slow push in both genders were comparable to that recorded for the 100 mg/kg oral dosing and notwithstanding the high C max ; it was evident from the cage side observations that the test article and delivery rate at this dose was well tolerated in rabbits.
  • short intravenous infusions in rabbits produced very high maximal ST-246 concentrations, which corresponded with the times of the observed clinical signs in the animals.
  • the AUC values although higher than corresponding oral dosing, did not correlate with clinical signs observed in these studies.
  • the pharmacokinetic parameters in rabbits were evaluated using a 15-minute IV infusion of 3 mg/kg ST-246.
  • ST-246 was administered via IV infusion over 4 hours via surgically implanted vascular access ports in NHP at doses of 1, 3, 10, 20, and 30 mg/kg.
  • the plasma concentrations increased throughout the 4-hour IV infusion of ST-246, reaching maximum concentrations at the end of the infusion (Table 29, Figure 18 ).
  • the maximum plasma concentrations (C max ) were higher after the IV infusions than after oral administration of equivalent doses (Table 29). At higher doses, the differences between the oral and IV C max concentrations increased.
  • the C max concentrations after oral administration increased less than dose-proportionally, while the peak plasma concentrations after IV infusion increased more than would be expected based on dose-proportionality.
  • the maximum plasma concentration after oral administration of ST-246 increased only 37-fold as the dose was increased 100-fold, from 0.3 to 30 mg/kg, while the exposure (AUC inf-obs ) increased closer to the proportional increase in dose, or 84-fold.
  • the elimination was also biphasic after oral administration, with plasma concentration time curves similar to those observed for rabbits.
  • the plasma elimination after IV infusion appeared to have at least two distinct phases, with a rapid distribution phase observed at the end of the infusion followed by a much slower terminal elimination phase ( Figure 18 ).
  • PK pharmacokinetic
  • the C max and AUC inf values increased dose-proportionally as the 4 hour IV-infused doses increased from 1 to 10 mg/kg, the increases in these values were greater than dose-proportional at the 20 and 30 mg/kg doses (Table 29).
  • the C max values for the 3 and 10 mg/kg doses were 2.7-fold and 11.5-fold higher, respectively, than that of the 1 mg/kg dose, while the corresponding values for the 20 and 30 mg/kg doses were 31-fold and 52-fold higher, respectively.
  • the AUC inf values increased 3.0, 11.0, 32, and 53-fold higher for the 3, 10, 20, and 30 mg/kg doses, respectively, compared to the 1 mg/kg dose.
  • the C max plasma concentrations were higher for the 4 hour infusions compared to the 6 hour infusions by approximately 50%, and the exposures calculated for shorter infusions were also higher, although only by approximately 20%.
  • Plasma concentrations after the end of infusions appeared to have at least two phases for all IV infusions, with a rapid distribution phase clearly observed just after the EOI followed by a slower terminal elimination phase.
  • the plasma concentration time curves appeared similar for the two infusion rates and doses, except for the T max and actual plasma concentrations.
  • a twice-a-day (BID) administration study of the two highest total daily doses was conducted via two 4 hour IV infusions initiated 12 hours apart over a single 24 hour time period ( Figures 20A and 20B ).
  • the individual doses were 10 and 15 mg/kg, so that the total daily doses were 20 and 30 mg/kg/day for the two dose groups, respectively.
  • Plasma concentrations increased over each of the 4 hour IV infusion periods with the C max for most animals occurring at the end of the infusion.
  • the plasma ST-246 concentrations decreased until the 12 hour time point, when the second 4 hour IV infusion began.
  • the plasma concentrations increased until the end of the infusion, and then declined over the remainder of the study.
  • the BID administration study had 4 males and 4 females in each dose group, providing a larger number with which to evaluate any potential gender differences in the pharmacokinetic parameters after IV infusion.
  • Student's t-test analysis of the PK parameters (C max , AUC last or AUC inf , Cl and V ss ) showed equivalence for the two genders, with the exception of the C max observed during the first phase of dosing at the 10 mg/kg/dose level (p ⁇ 0.05). Because there were no consistent differences between the pharmacokinetic parameters for the two genders, the final mean and standard deviation values for ST-246 were calculated by combining the data from both genders for each dose group.
  • the C max and AUC last values for the 15 mg/kg dose were 1.6-fold higher than those of the 10 mg/kg dose during the first 4 hour IV infusion.
  • the increase was slightly more, approximately 1.8-fold for the both C max and AUC values.
  • the terminal elimination half-lives, calculated from the second infusion, were essentially identical, 8.9 and 9.1 hours for the two doses, respectively. Clearance was also essentially equivalent for these two doses and within the range observed for the single IV infusions.
  • the antiviral efficacy of ST-246 against poxviruses has been demonstrated after oral administration in mice, rabbits, ground squirrels, prairie dogs, and NHP (3, 8-13).
  • the pharmacokinetics of ST-246 after oral administration has been thoroughly characterized in mice, NHP and humans, with limited information in rabbits, rats, and dogs.
  • a complete understanding of the pharmacokinetics is important in species in which the efficacy is also being evaluated, as the selection of the human therapeutic dose will necessarily be chosen based on the animal PK/PD relationship, due to the lack of evaluable orthopox disease in humans.
  • the most relevant animal species for human dose calculation is NHP.
  • the oral ST-246 study in NHP evaluated the pharmacokinetics over a dose range which encompassed those used in efficacy studies, from 0.3 to 30 mg/kg.
  • the C max as well as the exposure increased over this oral dose range, they increased less than dose-proportionally.
  • the C max increased only 37-fold over the 100-fold dose increase, while the exposure, as measured by the AUC inf , increased 84-fold, much closer to the 100-fold dose increase.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)

Claims (14)

  1. Flüssige pharmazeutische Formulierung, umfassend eine therapeutisch wirksame Menge von 4-Trifluormethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocyclo-prop[f]isoindol-2(1H)-yl)-benzamid (ST-246) und Hydroxypropyl-β-cyclodextrin oder Sulfobutylether-ß-cyclodextrin, und ferner umfassend einen oder mehrere pharmazeutisch verträgliche Bestandteile.
  2. Flüssige pharmazeutische Formulierung nach Anspruch 1, wobei die pharmazeutisch verträglichen Bestandteile ausgewählt sind aus der Gruppe bestehend aus Träger, Hilfsstoff, Verdünnungsmittel, Additiv, Füllstoff, Schmiermittel und Bindemittel.
  3. Flüssige pharmazeutische Formulierung nach Anspruch 1 oder Anspruch 2, wobei das Hydroxypropyl-ß-cyclodextrin in Mengen von 20 bis 40 Gew.-% vorliegt oder einen Substitutionsgrad zwischen 4,0 und 8,0 aufweist.
  4. Flüssige pharmazeutische Formulierung nach einem der Ansprüche 1 bis 3 mit einem pH zwischen 3 und 10.
  5. Flüssige pharmazeutische Formulierung nach einem der Ansprüche 1 bis 4 zur Verwendung bei der Behandlung von Orthopoxvirus-Infektionen und/oder Ekzema vaccinatum.
  6. Formulierung zur Verwendung nach Anspruch 5, wobei die flüssige Formulierung zur parenteralen Verabreichung, zur oralen Verabreichung, zur topischen Verabreichung oder zur intravenösen Verabreichung bestimmt ist.
  7. Formulierung zur Verwendung nach Anspruch 6, wobei die flüssige Formulierung zur intravenösen Verabreichung bestimmt ist, und wobei
    50 bis 500 mg ST-246 pro einzelner Sitzung einer intravenösen Verabreichung infundiert werden,
    200 bis 400 mg ST-246 pro einzelner Sitzung einer intravenösen Verabreichung infundiert werden,
    300 mg ST-246 pro einzelner Sitzung einer intravenösen Verabreichung infundiert werden,
    die Behandlung über einen Zeitraum von 7 bis 30 Tagen durchgeführt wird,
    die Behandlung über einen Zeitraum von 7 bis 15 Tagen durchgeführt wird,
    die Dauer jeder intravenösen Verabreichung 2 bis 24 Stunden beträgt,
    die Behandlung kontinuierlich im Verlauf der Behandlung bei einer Dosierung von 50 bis 500 mg ST-246 pro Tag erfolgt, oder
    die intravenöse Verabreichung während zwei Sitzungen pro Tag erfolgt, wobei die Dauer jeder Sitzung wahlweise 2 bis 12 Stunden beträgt.
  8. Verfahren zur Herstellung einer flüssigen Formulierung nach einem der Ansprüche 1 bis 4, umfassend die Schritte:
    a) Mischen von ST-246 mit dem Cyclodextrin in einem pharmazeutisch verträglichen flüssigen Träger; und
    b) gegebenenfalls Filtrieren der Mischung aus Schritt a).
  9. Verfahren nach Anspruch 8, wobei das ST-246 ausgewählt ist aus einer Gruppe bestehend aus ST-246 Polymorph Form I, ST-246 Polymorph Form II, ST-246 Polymorph Form III, ST-246 Polymorph Form IV, ST-246 Polymorph Form V und ST-246 Polymorph Form VI.
  10. Verfahren nach Anspruch 8, wobei die flüssige Formulierung auf einen pH-Wert zwischen 3 und 10 eingestellt wird, die Mischung aus Schritt (a) bei einer Temperatur von etwa 25 °C auf ein Löslichkeitsgleichgewicht gebracht wird, die Mischung aus Schritt (a) auf ein Löslichkeitsgleichgewicht bei einer Temperatur von etwa 37 °C gebracht wird, oder das ST-246 mit einem pharmazeutisch verträglichen Träger für etwa 72 Stunden gemischt wird.
  11. Flüssige Einheitsdosisformulierung, umfassend:
    a) einen 4-Trifluormethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamid (ST-246) Gehalt im Bereich von 2 mg/ml bis 20 mg/ml; und
    b) einen Hydroxypropyl-ß-cyclodextrin Gehalt im Bereich von 12,5 mg/ml bis 40 mg/ml.
  12. Flüssige Einheitsdosisformulierung nach Anspruch 11, ferner umfassend einen oder mehrere pharmazeutisch verträgliche Bestandteile, ausgewählt aus der Gruppe bestehend aus: Mannitol, Trehalosedehydrat, Lactosemonohydrat und gereinigtem Wasser, oder ausgewählt aus der Gruppe bestehend aus: Polyethylenglycol 400, Polysorbat 80 Polyethylenglykol 300 und gereinigtes Wasser.
  13. Flüssige Einheitsdosisformulierung nach Anspruch 11 oder Anspruch 12 mit einem pH-Bereich von 3,0 bis 10,0 oder mit einem Gesamtvolumen von 100 ml.
  14. Verfahren zur Herstellung einer wasserlöslichen festen pharmazeutischen 4-Trifluormethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-y1)-benzamid (ST-246) Formulierung, umfassend:
    a) Mischen von ST-246 mit Hydroxypropyl-ß-cyclodextrin oder Sulfobutylether-ß-cyclodextrin in einem pharmazeutisch verträglichen flüssigen Träger;
    b) gegebenenfalls Filtrieren des Gemisches von Schritt a); und
    c) Lyophilisieren der Mischung.
EP11815188.5A 2010-08-05 2011-08-02 St-246-flüssigformulierungen und verfahren dafür Active EP2600715B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08
PCT/US2011/046260 WO2012018810A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Publications (3)

Publication Number Publication Date
EP2600715A1 EP2600715A1 (de) 2013-06-12
EP2600715A4 EP2600715A4 (de) 2016-04-20
EP2600715B1 true EP2600715B1 (de) 2019-12-11

Family

ID=45559790

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11815188.5A Active EP2600715B1 (de) 2010-08-05 2011-08-02 St-246-flüssigformulierungen und verfahren dafür

Country Status (15)

Country Link
US (5) US9233097B2 (de)
EP (1) EP2600715B1 (de)
JP (1) JP5898196B2 (de)
KR (1) KR101868117B1 (de)
CN (2) CN103281898A (de)
AR (1) AR082566A1 (de)
AU (1) AU2011285871B8 (de)
BR (1) BR112013002646B1 (de)
CA (1) CA2807528C (de)
DK (1) DK2600715T3 (de)
IL (1) IL224430B (de)
MX (2) MX347795B (de)
SG (3) SG187243A1 (de)
WO (1) WO2012018810A1 (de)
ZA (1) ZA201300930B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (zh) * 2013-08-28 2018-09-04 山东新时代药业有限公司 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺
US10406103B2 (en) 2013-11-19 2019-09-10 Siga Technologies Inc. Rehydration of micronized tecovirmimat monohydrate
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
US10488733B2 (en) 2015-04-10 2019-11-26 Bae Systems Plc Long range electromagnetic radiation sensor having a control system to heat and/or ionize the air within three-dimensional portions of an atmospheric volume
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US20230082992A1 (en) * 2021-09-11 2023-03-16 Viron Therapeutics LLC Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CN116211821A (zh) * 2023-02-06 2023-06-06 青岛增益安生物科技有限公司 一种特考韦瑞的药物混合方式
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215027A1 (en) 2002-03-21 2003-10-08 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
PL1638938T3 (pl) * 2003-06-20 2017-10-31 Siga Tech Inc Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom
WO2006067584A1 (en) * 2004-12-23 2006-06-29 Pfizer Limited 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
ES2526903T3 (es) * 2005-10-26 2015-01-16 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
WO2008063634A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
CA2866037C (en) * 2007-04-23 2017-05-16 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
DK2313111T3 (da) * 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US9907859B2 (en) 2018-03-06
IL224430B (en) 2019-09-26
CA2807528A1 (en) 2012-02-09
CN106074370A (zh) 2016-11-09
AU2011285871A8 (en) 2015-05-14
MX368106B (es) 2019-09-19
SG10201506031UA (en) 2015-09-29
AU2011285871A1 (en) 2013-02-21
ZA201300930B (en) 2015-11-25
KR101868117B1 (ko) 2018-06-18
JP2013532729A (ja) 2013-08-19
WO2012018810A9 (en) 2012-04-05
SG10202105262QA (en) 2021-06-29
CN103281898A (zh) 2013-09-04
EP2600715A4 (de) 2016-04-20
AU2011285871B2 (en) 2015-04-23
US20180185514A1 (en) 2018-07-05
KR20130135836A (ko) 2013-12-11
US20140011854A1 (en) 2014-01-09
US10864282B2 (en) 2020-12-15
SG187243A1 (en) 2013-02-28
MX2013001389A (es) 2013-06-07
US9233097B2 (en) 2016-01-12
JP5898196B2 (ja) 2016-04-13
BR112013002646A2 (de) 2013-02-04
US20200138974A1 (en) 2020-05-07
US20160082128A1 (en) 2016-03-24
BR112013002646B1 (pt) 2022-01-04
US20190038767A1 (en) 2019-02-07
US10124071B2 (en) 2018-11-13
CA2807528C (en) 2018-09-25
WO2012018810A1 (en) 2012-02-09
US10576165B2 (en) 2020-03-03
AR082566A1 (es) 2012-12-19
MX347795B (es) 2017-05-12
EP2600715A1 (de) 2013-06-12
AU2011285871B8 (en) 2015-05-14
DK2600715T3 (da) 2020-03-16

Similar Documents

Publication Publication Date Title
US10864282B2 (en) ST-246 liquid formulations and methods
US6869939B2 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU2002254309B2 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030073665A1 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AU2002254309A1 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
WO2004075921A1 (en) Inclusion complex of artemisinin or derivates thereof with cyclodextrins
KR20050116368A (ko) 약물의 멘톨 용액
KR101130754B1 (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
US20230210830A1 (en) Stable pharmaceutical composition of nimodipine
KR20120140591A (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184639

Country of ref document: HK

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160322

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101AFI20160316BHEP

Ipc: A61K 9/00 20060101ALI20160316BHEP

Ipc: A61P 31/12 20060101ALI20160316BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181002

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011063985

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A01N0043040000

Ipc: A61K0047690000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/715 20060101ALI20190329BHEP

Ipc: A61K 31/724 20060101ALI20190329BHEP

Ipc: A61K 9/19 20060101ALI20190329BHEP

Ipc: A61K 47/69 20170101AFI20190329BHEP

Ipc: A61K 9/00 20060101ALI20190329BHEP

Ipc: A61P 31/12 20060101ALI20190329BHEP

Ipc: A61K 9/08 20060101ALI20190329BHEP

Ipc: A61K 47/40 20060101ALI20190329BHEP

Ipc: A61K 31/4035 20060101ALI20190329BHEP

Ipc: A61K 47/10 20170101ALI20190329BHEP

INTG Intention to grant announced

Effective date: 20190508

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STONE, MELIALANI, A.C.L.

Inventor name: BOLKEN, TOVE', C.

Inventor name: HRUBY, DENNIS, E.

Inventor name: KASI, GOPI, KRISHNA

Inventor name: SAMUEL, PETER, N.K.

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR, R.

Inventor name: WEIMERS, WILLIAM, C.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HRUBY, DENNIS E.

Inventor name: KASI, GOPI, KRISHNA

Inventor name: STONE, MELIALANI A.C.L.

Inventor name: BOLKEN, TOVE' C.

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR R.

Inventor name: SAMUEL, PETER N.K.

Inventor name: WEIMERS, WILLIAM C.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1211513

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011063985

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200311

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191211

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200311

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200312

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200411

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011063985

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1211513

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191211

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230828

Year of fee payment: 13

Ref country code: CH

Payment date: 20230902

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230825

Year of fee payment: 13

Ref country code: DK

Payment date: 20230829

Year of fee payment: 13

Ref country code: DE

Payment date: 20230829

Year of fee payment: 13

Ref country code: BE

Payment date: 20230828

Year of fee payment: 13